Dolutegravir-associated resistance mutations after first-line treatment failure in Brazil
- Standort
-
Deutsche Nationalbibliothek Frankfurt am Main
- Umfang
-
Online-Ressource, 1 online resource.
- Sprache
-
Englisch
- Erschienen in
-
Dolutegravir-associated resistance mutations after first-line treatment failure in Brazil ; volume:23 ; number:1 ; day:24 ; month:5 ; year:2023 ; pages:1-10 ; date:12.2023
BMC infectious diseases ; 23, Heft 1 (24.5.2023), 1-10, 12.2023
- Urheber
-
Diaz, Ricardo Sobhie
Hunter, James R.
Camargo, Michelle
Dias, Danilo
Galinskas, Juliana
Nassar, Isabela
Lima, Isaac Barbosa de
Caldeira, Debora Bellini
Sucupira, Maria Cecilia
Schechter, Mauro
- Beteiligte Personen und Organisationen
-
SpringerLink (Online service)
- DOI
-
10.1186/s12879-023-08288-8
- URN
-
urn:nbn:de:101:1-2023091012585693644731
- Rechteinformation
-
Open Access; Der Zugriff auf das Objekt ist unbeschränkt möglich.
- Letzte Aktualisierung
-
14.08.2025, 10:51 MESZ
Datenpartner
Dieses Objekt wird bereitgestellt von:
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Beteiligte
- Diaz, Ricardo Sobhie
- Hunter, James R.
- Camargo, Michelle
- Dias, Danilo
- Galinskas, Juliana
- Nassar, Isabela
- Lima, Isaac Barbosa de
- Caldeira, Debora Bellini
- Sucupira, Maria Cecilia
- Schechter, Mauro
- SpringerLink (Online service)
Ähnliche Objekte (12)
Probing Resistance Mutations in Retroviral Integrases by Direct Measurement of Dolutegravir Fluorescence
Patterns of drug resistance mutations after failure of first-line NNRTI-based antiretroviral therapy in Western India
GBA mutations and Parkinson's disease in Brazil
PIK3CA mutations confer resistance to first-line chemotherapy in colorectal cancer
Dolutegravir: Nutzenbewertung gemäß § 35a SGB V
Interaction analysis of statistically enriched mutations identified in Cameroon recombinant subtype CRF02_AG that can influence the development of Dolutegravir drug resistance mutations
High rates of transmitted NNRTI resistance among persons with acute HIV infection in Malawi: implications for first-line dolutegravir scale-up
Cost-Utility Analysis of Dolutegravir- Versus Efavirenz-Based Regimens as a First-Line Treatment in Adult HIV/AIDS Patients in Ethiopia
Knowledge and perceptions about Dolutegravir and Dolutegravir counselling: a qualitative study among women living with HIV
Creation of a long-acting nanoformulated dolutegravir
Should dolutegravir always be withheld in people with HIV on dolutegravir with incident diabetes mellitus? a case report
Modifying dolutegravir to PrEPare for long life
Probing Resistance Mutations in Retroviral Integrases by Direct Measurement of Dolutegravir Fluorescence
Patterns of drug resistance mutations after failure of first-line NNRTI-based antiretroviral therapy in Western India
GBA mutations and Parkinson's disease in Brazil
PIK3CA mutations confer resistance to first-line chemotherapy in colorectal cancer
Dolutegravir: Nutzenbewertung gemäß § 35a SGB V
Interaction analysis of statistically enriched mutations identified in Cameroon recombinant subtype CRF02_AG that can influence the development of Dolutegravir drug resistance mutations
High rates of transmitted NNRTI resistance among persons with acute HIV infection in Malawi: implications for first-line dolutegravir scale-up
Cost-Utility Analysis of Dolutegravir- Versus Efavirenz-Based Regimens as a First-Line Treatment in Adult HIV/AIDS Patients in Ethiopia
Knowledge and perceptions about Dolutegravir and Dolutegravir counselling: a qualitative study among women living with HIV
Creation of a long-acting nanoformulated dolutegravir
Should dolutegravir always be withheld in people with HIV on dolutegravir with incident diabetes mellitus? a case report
Modifying dolutegravir to PrEPare for long life
Probing Resistance Mutations in Retroviral Integrases by Direct Measurement of Dolutegravir Fluorescence
Patterns of drug resistance mutations after failure of first-line NNRTI-based antiretroviral therapy in Western India
GBA mutations and Parkinson's disease in Brazil
PIK3CA mutations confer resistance to first-line chemotherapy in colorectal cancer
Dolutegravir: Nutzenbewertung gemäß § 35a SGB V
Interaction analysis of statistically enriched mutations identified in Cameroon recombinant subtype CRF02_AG that can influence the development of Dolutegravir drug resistance mutations
High rates of transmitted NNRTI resistance among persons with acute HIV infection in Malawi: implications for first-line dolutegravir scale-up
Cost-Utility Analysis of Dolutegravir- Versus Efavirenz-Based Regimens as a First-Line Treatment in Adult HIV/AIDS Patients in Ethiopia
Knowledge and perceptions about Dolutegravir and Dolutegravir counselling: a qualitative study among women living with HIV
Creation of a long-acting nanoformulated dolutegravir
Should dolutegravir always be withheld in people with HIV on dolutegravir with incident diabetes mellitus? a case report